p53 immunohistochemistry for distinguishing reactive mesothelium from low grade ovarian carcinoma

被引:1
作者
Pindzola, JA
Kovatich, AJ
Bibbo, M
机构
[1] Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Cell Biol & Anat, Div Immunohistochem, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Cell Biol & Anat, Div Cytopathol, Philadelphia, PA 19107 USA
关键词
p53; protein; immunohistochemistry; ovarian neoplasms;
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
OBJECTIVE: To determine the utility of immunohistochemical staining for p53 in cell block material for distinguishing reactive mesothelium from borderline or low grade ovarian carcinoma. STUDY DESIGN: Paraffin-embedded cell blocks from paracentesis and pelvic wash fluid of 44 cases of ovarian carcinoma and 20 cases containing only reactive mesothelium were immunostained for p53 using monoclonal antibody DO-7. Tumor grades ranged from borderline to high grade and were serous papillary (33), clear cell (3), mucinous (2), endometrioid (2), mixed serous papillary/clear cell (3) and undifferentiated (2). The three authors independently evaluated the staining, including estimation of the percentage and intensity of positive nuclear staining. RESULTS: A separation of positive from negative cases was seen when staining intensify was considered the critical parameter; moderate to strong staining was considered truly positive. Seventy-three percent (8/11) of borderline tumors, 80% (8/10) of low grade tumors and 65% (15/23) of intermediate to high grade tumors showed moderate to strong positivity. Percentage of staining was a less-reliable parameter as 25% of negative cases were positive by this assessment. CONCLUSION: p53 Immunohistochemistry, using monoclonal antibody DO-7 combined with standard morphologic evaluation, may be useful in distinguishing benign reactive mesothelium from borderline or low grade ovarian carcinoma.
引用
收藏
页码:31 / 36
页数:6
相关论文
共 15 条
  • [1] EVALUATION OF 6 ANTIBODIES FOR IMMUNOHISTOCHEMISTRY OF MUTANT P53 GENE-PRODUCT IN ARCHIVAL COLORECTAL NEOPLASMS
    BAAS, IO
    MULDER, JWR
    OFFERHAUS, GJA
    VOGELSTEIN, B
    HAMILTON, SR
    [J]. JOURNAL OF PATHOLOGY, 1994, 172 (01) : 5 - 12
  • [2] WHAT DO WE KNOW ABOUT THE ORIGIN OF CA-125
    BISCHOF, P
    [J]. EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1993, 49 (1-2): : 93 - 98
  • [3] p53 and HER-2/neu overexpression in ovarian borderline tumors
    Eltabbakh, GH
    Belinson, JL
    Kennedy, AW
    Biscotti, CV
    Casey, G
    Tubbs, RR
    [J]. GYNECOLOGIC ONCOLOGY, 1997, 65 (02) : 218 - 224
  • [4] P53 MUTATIONS IN HUMAN CANCERS
    HOLLSTEIN, M
    SIDRANSKY, D
    VOGELSTEIN, B
    HARRIS, CC
    [J]. SCIENCE, 1991, 253 (5015) : 49 - 53
  • [5] IMMUNOHISTOCHEMICAL DETECTION OF P53 PROTEIN IN BORDERLINE AND MALIGNANT SEROUS OVARIAN-TUMORS
    KLEMI, PJ
    TAKAHASHI, S
    JOENSUU, H
    KIILHOLMA, P
    NARIMATSU, E
    MORI, M
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1994, 13 (03) : 228 - 233
  • [6] p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor
    Lee, JH
    Kang, YS
    Park, SY
    Kim, BG
    Lee, ED
    Lee, KH
    Park, KB
    Kavanagh, JJ
    Wharton, JT
    [J]. CANCER GENETICS AND CYTOGENETICS, 1995, 85 (01) : 43 - 50
  • [7] MILNER BJ, 1993, CANCER RES, V53, P2128
  • [8] Mullick SS, 1996, ACTA CYTOL, V40, P855
  • [9] Rosai J, 1996, ACKERMANS TXB SURG P, P1461
  • [10] SHERMAN ME, 1994, BLAUSTEINS PATHOLOGY, P1123